RESUSCITEC GMBH

Their core work

RESUSCITEC is a German medical technology SME specializing in advanced resuscitation systems for cardiac arrest and critical emergency care. Their core product is the CIRD — Controlled Integrated Resuscitation Device — a system designed to push beyond the current physiological limits of standard resuscitation protocols. Alongside device development, they have validated a panel of 11 biomarkers that support both diagnosis and therapeutic decision-making during resuscitation. They operate at the intersection of emergency medicine hardware and clinical diagnostics, aiming to bring a single integrated solution to emergency responders and hospital intensive care units.

What they specialise in

How they've shifted over time

RESUSCITEC's two H2020 projects both launched in the 2015–2016 window and revolve entirely around a single technology platform — the CIRD system. Their trajectory follows a textbook SME innovation arc: start with a small Phase 1 feasibility and validation grant (CIRDvalid, €50K), then secure a larger Innovation Action to bring the device closer to market (CIRDinnova, €1.5M, running to 2022). There is no visible pivot or broadening of focus; rather, this is a company that went deep on one problem and one product over the full H2020 period.

RESUSCITEC is a focused single-product company moving along a commercialization path — partners should expect a technology provider with deep domain specificity in emergency resuscitation rather than a broad research collaborator.

How they like to work

RESUSCITEC has led one project as coordinator and joined one as participant, suggesting they are capable of both roles but default to small, tight consortia — only 3 unique partners across their full H2020 portfolio. Their collaborations appear purpose-built around the CIRD technology rather than broad network-building. Working with them likely means a focused, product-centric partnership where their device or clinical expertise is the central asset.

RESUSCITEC has worked with just 3 partners across 3 countries, reflecting a deliberately small and targeted collaboration footprint. Their network appears clinically oriented — likely academic hospitals or research institutes needed for device validation — rather than a broad industrial or cross-sector web.

What sets them apart

RESUSCITEC occupies a narrow but high-stakes niche: they are building an integrated device specifically designed to extend the physiological boundaries of resuscitation, combining hardware, diagnostics, and clinical evidence in one package. Very few SMEs operate at this intersection of emergency medicine device engineering and biomarker-based treatment guidance. For a consortium needing a credentialed resuscitation technology partner with both a validated product platform and EU-funded clinical evidence behind it, RESUSCITEC is a rare find.

Highlights from their portfolio

• CIRDinnova
  The flagship project with €1.5M in EU Innovation Action funding, targeting real-world deployment of the CIRD device — the longest-running and highest-investment project in the portfolio, running six years to 2022.
• CIRDvalid
  Coordinator-led SME Phase 1 project that validated 11 clinical biomarkers, providing the diagnostic evidence base underpinning the full CIRD system.